Latest Hospitality News

RAM Essential Services Property Fund reported solid FY25 results, highlighting portfolio growth, strategic capital recycling, and a clear transition towards a pure healthcare real estate focus.

ReadyTech reported a solid 7.1% revenue increase in FY25, driven by $15.4 million in new enterprise contracts and a strategic push into AI-enhanced SaaS products. The company’s strong pipeline and AI initiatives set the stage for accelerated growth in FY26 and beyond.

ReadyTech Holdings Limited reported a 7.1% increase in revenue to $121.8 million for FY25 but swung to a $16.1 million loss after tax, driven by a significant impairment and strategic investments. The company completed the acquisition of CouncilWise Pty Ltd, aiming to strengthen its local government software offerings.

SiteMinder Limited reported robust FY25 results with a 27.2% constant currency organic ARR increase and a return to positive underlying EBITDA, driven by its innovative Smart Platform and expanding global footprint.

SiteMinder Limited reported a 17.7% revenue increase to $224.3 million in FY2025, alongside a reduced net loss and positive underlying EBITDA, driven by its innovative Smart Platform strategy and expanding customer base.

Paragon Care Limited reported solid FY25 results with revenue climbing to $3.61 billion and underlying EBITDA rising 3%, driven by successful integration and expansion into new healthcare segments.

Winton Land Limited reported a 10.5% revenue decline to NZD 155.4 million for FY25, with net profit after tax down 34.4%, as subdued Auckland markets and economic headwinds persist. The company is focusing on South Island developments and Fast-track approvals to navigate the downturn.

EBOS Group Limited reported solid FY25 results with 12% revenue growth and strategic acquisitions, setting sights on continued expansion and operational efficiency in FY26.

EBOS Group Limited reported a steady FY25 with 12% revenue growth and EBITDA in line with guidance, driven by strong healthcare and animal care segments. The company signals confidence with maintained dividends and a positive FY26 outlook.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.